Alternating electric field therapy

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, February 22, 2024
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Glioblastoma, NSCLC, Regulation, TRIDENT, PMA, Investment, Marketing, FDA, Partnership, Food, File, EST, Growth, Clinical trial, Loss, Alternating electric field therapy, Disclosure, GBM, Prescription, European, Lung cancer, Regulation Fair Disclosure, Webcast, Patient, METIS, Survival, Temozolomide, Cancer, Pharmaceutical industry

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2023.

Key Points: 
  • Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2023.
  • “In 2023, we reached many milestones in our commercial, clinical and product development programs,” said Asaf Danziger, Novocure’s Chief Executive Officer.
  • Operational updates for the fourth quarter ended December 31, 2023:
    1,564 prescriptions were received in the quarter, an increase of 14% year-over-year.
  • Novocure will host a conference call and webcast to discuss fourth quarter and full year 2023 financial results at 8:00 a.m. EST today, Thursday, February 22, 2024.

Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting

Retrieved on: 
Friday, November 10, 2023
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Neurology, Other Science, Research, Science, Clinical Trials, CNS, Neoplasm, Vancouver Convention Centre, Safety, Annual general meeting, PST, Quality, Radiosurgery, Pakistan Society of Neuro-Oncology, Barrier, American Brain Tumor Association, TRIDENT, GBM, Chemoradiotherapy, Patient, TMZ, TTF, Radiation, Alternating electric field therapy, Quality of life, Lung cancer, Neuro, Biomarker, Trial of the century, METIS, Survival, TIGER, Central nervous system, Immunotherapy, Skin, Oligodendroglioma, SNO, NSCLC, Medical imaging, Pharmaceutical industry, Communications satellite, Glioblastoma

The 2023 SNO Annual Meeting will also mark the debut of Novocure’s new Optune Gio™ brand.

Key Points: 
  • The 2023 SNO Annual Meeting will also mark the debut of Novocure’s new Optune Gio™ brand.
  • Long-term global post-marketing surveillance data from pediatric, adult and elderly patients with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy.
  • 7:30 p.m. PST on Friday, Nov. 17
    Adopting Tumor Treating Fields (TTFields) therapy for glioblastoma and other solid cancers: challenges and opportunities.
  • 7:30 p.m. PST on Friday, Nov. 17
    Development of Tumor Treating Fields (TTFields) arrays for treatment of head tumors in mice models.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)

Retrieved on: 
Tuesday, August 15, 2023
Clinical trial, Alternating electric field therapy, Lung cancer, Suite, Patient, Standard of care, Court, Defendant, FDA, GPM, News, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On June 6, 2023, NovoCure announced “positive results” from the clinical trial evaluating its LUNAR Tumor Treating Fields therapy in treating non-small cell lung cancer.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)

Retrieved on: 
Thursday, August 17, 2023
Class Action Lawsuit, Professional Services, Legal, Clinical trial, Alternating electric field therapy, Law, Lung cancer, Suite, Patient, Standard of care, Court, Defendant, FDA, News, Pharmaceutical industry

The Law Offices of Frank R. Cruz reminds investors of the upcoming August 18, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR ) securities between January 5, 2023 and June 5, 2023, inclusive (the “Class Period”).

Key Points: 
  • The Law Offices of Frank R. Cruz reminds investors of the upcoming August 18, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR ) securities between January 5, 2023 and June 5, 2023, inclusive (the “Class Period”).
  • On June 6, 2023, NovoCure announced “positive results” from the clinical trial evaluating its LUNAR Tumor Treating Fields therapy in treating non-small cell lung cancer.
  • On this news, NovoCure’s stock price fell $35.51, or 43%, to close at $47.00 per share on June 6, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

NOVOCURE 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR

Retrieved on: 
Wednesday, August 16, 2023
Class Action Lawsuit, Professional Services, Legal, Lung cancer, Alternating electric field therapy, District court, KSF, Patient, Special warfare combatant-craft crewmen, Court, News, Pharmaceutical industry

This action is pending in the United States District Court for the Southern District of New York.

Key Points: 
  • This action is pending in the United States District Court for the Southern District of New York.
  • NovoCure and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • On this news, shares of NovoCure fell $35.51 per share, or 43.04%, to close at $47.00 per share on June 6, 2023.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms.

Global Skin Toner Market Outlook 2023-2028: Exfoliating Toners on the Rise, Organic Skin Toners in High Demand - ResearchAndMarkets.com

Retrieved on: 
Monday, August 14, 2023
Cosmetics, Retail, Partnership, Alternating electric field therapy, Vaccination, COVID-19, Bee, Shiseido, Compound annual growth rate, Market, US, Beauty, Procter & Gamble, L'Oréal, Distribution, Burt's Bees, Artificial intelligence, Growth, Johnson & Johnson, Skin

This growth is driven by increasing consumer consciousness about appearance and skincare, leading to a surge in demand for exfoliating toners.

Key Points: 
  • This growth is driven by increasing consumer consciousness about appearance and skincare, leading to a surge in demand for exfoliating toners.
  • The global skin toner market is divided into two categories: organic and conventional.
  • The rising preference for natural and chemical-free products has contributed to the increasing demand for organic skin toners.
  • Government-imposed bans on international travel further hindered collaboration and partnership plans, affecting the consumer goods industry, including the skin toner market.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)

Retrieved on: 
Tuesday, August 8, 2023
Clinical trial, Alternating electric field therapy, Lung cancer, Suite, Patient, Standard of care, Court, Defendant, FDA, GPM, News, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On June 6, 2023, NovoCure announced “positive results” from the clinical trial evaluating its LUNAR Tumor Treating Fields therapy in treating non-small cell lung cancer.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)

Retrieved on: 
Tuesday, August 1, 2023
Clinical trial, Alternating electric field therapy, Lung cancer, Suite, Patient, Standard of care, Court, Defendant, FDA, GPM, News, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On June 6, 2023, NovoCure announced “positive results” from the clinical trial evaluating its LUNAR Tumor Treating Fields therapy in treating non-small cell lung cancer.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)

Retrieved on: 
Thursday, July 27, 2023
Clinical trial, Alternating electric field therapy, Lung cancer, Suite, Patient, Standard of care, Court, Defendant, FDA, GPM, News, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On June 6, 2023, NovoCure announced “positive results” from the clinical trial evaluating its LUNAR Tumor Treating Fields therapy in treating non-small cell lung cancer.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NovoCure Limited (NVCR)

Retrieved on: 
Wednesday, July 19, 2023
Clinical trial, Alternating electric field therapy, Lung cancer, Suite, Patient, Standard of care, Court, Defendant, FDA, GPM, News, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On June 6, 2023, NovoCure announced “positive results” from the clinical trial evaluating its LUNAR Tumor Treating Fields therapy in treating non-small cell lung cancer.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles